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Fluorine chemistry has represented a hot topic in drug research over the last decade. Because of their
pharmaceutical potential, ﬂuorine-containing amino acids and related derivatives have acquired high
importance among medicinal chemists. Therefore their synthesis and the development of various syn-
thetic methods for these types of molecular scaffolds have gained increasing interest in synthetic organic
chemistry. The current review focuses on synthetic protocols towards ﬂuorine-containing amino acid
derivatives through late-stage ﬂuorination with various nucleophilic reagents, describing the access of
various open-chain and cyclic a-, b-, g-amino acid derivatives.
© 2018 Elsevier Ltd. All rights reserved.Contents
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. Kiss).1. Introduction
1.1. Importance of ﬂuorination and ﬂuorinated amino acids
Incorporation of ﬂuorine into the structure of an organic
molecule attracted increasing attention in the last decades, because
of possible advantages originating from the unique properties of
the ﬂuorine atom and the carbon-ﬂuorine bond. For example,
List of abbreviations
aHF anhydrous hydrogen ﬂuoride or liquid HF
AIBN azobisisobutyronitrile
CDI 1,10-carbonyldiimidazole
DAST diethylaminosulfur triﬂuoride
DABCO 1,4-diazabicyclo[2.2.2]octane
DBU 1,8-diazabicyclo(5.4.0)undec-7-ene
DCC dicyclohexyl carbodiimide
DCE 1,2-dichloroethane
DME 1,2-dimethoxyethane
DEAD diethyl azodicarboxylate
Deoxoﬂuor bis(2-methoxyethyl)aminosulfur triﬂuoride
DIAD diisopropyl azodicarboxylate
DMAP 4-dimethylaminopyridine
DMP Dess-Martin periodinane
EDC 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide
FCBT O-[(1s,3R)-3-ﬂuorocyclobutyl] L-tyrosine
FEMAET O-2((2-ﬂuoroethyl)methylamino)ethyl L-tyrosine
FluoLead 4-tert-butyl-2,6-dimethylphenylsulfur triﬂuoride
FNT O-[2-ﬂuoro-3-(2-nitro-1H-imidazole-1-yl)propyl] L-
tyrosine
HOBt 1-hydroxybenzotriazole
LDA lithium diisopropylamide
L-Selectride: lithium tri-sec-butyl(hydrido)borate
mCPBA 3-chloroperbenzoic acid
Morph-DAST morpholinosulfur triﬂuoride
MOST morpholinosulfur triﬂuoride
NBS N-bromosuccinimide
NCS N-chlorosuccinimide
Ns nosyl, 4-nitrobenzenesulfonyl
PDC pyridinium dichromate
Pth phthalyl
TBS tert-butyldimethylsilyl
TEMPO (2,2,6,6-tetramethyl-piperidyl-1-yl)oxyl
TFA triﬂuoroacetic acid
TIPS triisopropylsilyl
TMS trimethylsilyl
XtalFluor-E diethylaminodiﬂuorosulﬁnium tetraﬂuoroborate
XtalFluor-M morpholinodiﬂuorosulﬁnium tetraﬂuoroborate
A.M. Remete et al. / Tetrahedron 74 (2018) 6367e64186368thanks to the high electronegativity of ﬂuorine, CeF bonds are
polar, while CeH bonds are non-polar enabling dipoleedipole and
dipoleecharge interactions, which can enhance binding [1e7].
However, the CeF bond is also relatively nonpolarizable, which
makes it only a weak H-bond acceptor [2,7]. Consequently, solva-
tion by water is not too effective. The overall result of these two
effects is polar hydrophobicity affecting the lipophilicity of the
molecule, which is a key parameter in medicinal chemistry [1e5,7].Scheme 1. Effects of ﬂuorination on drug molecules. Top: ﬂuorine atom increases binding
interaction [6]. Bottom: prevention of unwanted metabolic changes in the case of ezetimib
Scheme 2. Some ﬂuorinated aThe high electronegativity of ﬂuorine also inﬂuences pKa values of
nearby functional groups [1e5,7]. This, together with polar hy-
drophobicity, can have a substantial effect on bioavailability,
another key parameter [4,5,7]. CeF bonds are stronger than CeH
bonds, which can greatly increase metabolic stability [1e5,7].
Importantly, the size of F is between the size of H and OH and it
means that ﬂuorine is isosteric with these groups. Accordingly,
ﬂuorination often leaves conformation of the molecule almostof atorvastatin, used to block cholesterol synthesis through an electrostatic CeF$$$Ndþ
e, another cholesterol-lowering medication [7].
mino acid drugs [15e17].
A.M. Remete et al. / Tetrahedron 74 (2018) 6367e6418 6369intact, although it can also induce conformational changes through
stereoelectronic effects [1e5,7].
As a result of the above effects, ﬂuorinated drug molecules
became common [8] and in the 2000s the ratio of ﬂuorinated
molecules within newly-approved drugs started to increase [5].
Some good examples are shown on Scheme 1. Incorporation of 18F
atom (t1/2¼110min) to produce radiopharmaceuticals is also an
emerging area [1,2,9].
Amino acids have enormous signiﬁcance in the pharmaceutical
chemistry in accordance with their versatility, bioactivity and
structural diversity. Because of the importance of ﬂuorination,
ﬂuorinated amino acid derivatives also gained increasing attention
[1,10e14]. These compounds can often be incorporated into pro-
teins without structural changes enabling investigation of protein
structures with 19F NMR (or, in the case of ﬂuorinated Trp, withScheme 3. Several bioactive ﬂuorinate
Scheme 4. Mechanisms of deoxyﬂuorinations with SF4. Exchanging OH forspectroﬂuorimetry) and enzyme mechanisms [1,13]. The latter can
be achieved with ﬂuorinated amino acid substrates too [1,14].
Research of peptide-based drugs can also beneﬁt from ﬂuorinated
amino acids, because ﬂuorination of amino acids often causes
conformational changes and restrictions. Namely, ﬂuorine prefers
gauche arrangement relative to vicinal highly electronegative het-
eroatoms and antiperiplanar arrangement relative to vicinal oxo
groups. These features can be useful to achieve speciﬁc secondary
structures or side-chain conformations [12,14]. Successful devel-
opment of ﬂuorinated amino acid drugs (Scheme 2) also proved the
signiﬁcance of this family of compounds in pharmaceutical chem-
istry. Examples are (±)-Eﬂornithine (4) introduced for the treat-
ment of trypanosomiasis (sleeping sickness) [15] and later also
applied topically against facial hirsutism in women [16], as well as
Sitagliptin (5), an antidiabetic drug, the ﬁrst dipeptidyl peptidase IVd amino acid derivatives [18e23].
F has a strong tendency to shift towards SN1-type substitution [2,30].
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Scheme 5. Mechanisms of deoxyﬂuorinations with dialkylaminosulfur triﬂuorides
[2,36,37].
Scheme 6. Mechanisms of deoxyﬂuorin
Scheme 7. Mechanisms of deoxyﬂu
A.M. Remete et al. / Tetrahedron 74 (2018) 6367e64186370inhibitor [17].
Selected representatives of other bioactive ﬂuorinated amino
acid derivatives are shown on Scheme 3. In the case of mGluR4
agonist (±)-6, ﬂuorination increased binding afﬁnity nearly
sevenfold [18]. Fludalanine 7 has a broad spectrum of antibiotic
activities [19]. Fluorinated rhodopeptin analogue 8 has antifungal
activity similar to its parent compound associated with decreased
toxicity [20]. Fluorinated proline moieties can be found in dipep-
tidyl peptidase IV inhibitor cis-LC15-0133 (9) [21] and second-
generation HIV protease inhibitors 10 and 11 [22]. Compound 12
with superior citotoxicity is an analogue of the antitumor docetaxel
[23].
The increasing popularity of ﬂuorinated molecules resulted in a
signiﬁcant development of ﬂuorination techniques in the last de-
cades [3]. Currently, both electrophilic and nucleophilic ﬂuorine
sources as well as ﬂuorinated building blocks are available at
acceptable prices. One particularly useful method is deoxyﬂuori-
nation, a subtype of nucleophilic ﬂuorination, when incorporationations with XtalFluor reagents [36].
orinations with FluoLead [41].
Scheme 8. Synthesis of protected FNT (16) [19].
Scheme 9. Synthesis of L-FCBT (24) [46].
A.M. Remete et al. / Tetrahedron 74 (2018) 6367e6418 6371
Scheme 10. Synthesis of FEMAET (29) [47].
Scheme 11. Synthesis of CHF2-containing phosphotyrosine analogue 33 [48].
A.M. Remete et al. / Tetrahedron 74 (2018) 6367e64186372of ﬂuorine and oxygen removal take place simultaneously. However, ﬂuorination is still challenging [3], especially when
Scheme 12. Synthesis of CH2F-containing phosphotyrosine analogue 38 [49].
Scheme 13. Preparation of dipeptide 42 with ﬂuoromethyl-phosphotyrosine moiety [50].
A.M. Remete et al. / Tetrahedron 74 (2018) 6367e6418 6373ﬂuorine has to be introduced into highly-functionalized scaffolds
[24,25], which is typical for late-stage ﬂuorination.
Because the previous reviews addressing the syntheses of
ﬂuorinated amino acids [10e14] do not focus on this particular
ﬂuorination strategy, the aim of this review is to survey recentliterature data with respect to the synthesis of ﬂuorinated amino
acid derivatives through late-stage deoxyﬂuorination with nucle-
ophilic ﬂuorinating reagents, which are used most commonly for
this transformation. First, deoxyﬂuorinating reagents will be
introduced brieﬂy. Then, the synthesis of ﬂuorinated amino acids
Scheme 14. Syntheses of N-protected ﬂuoroalanine derivatives [51,52]. The enantiomeric compounds were also accessed analogously from (R)-43a [(R)-44: 76%, (S)-45: 71%, (S)-46:
92% in 92% ee, (S)-47b: 99% in 98% ee].
Scheme 15. Synthesis of N-propargyl-3-ﬂuoro-L-alanine [53].
A.M. Remete et al. / Tetrahedron 74 (2018) 6367e64186374will be discussed, grouped into six parts: acyclic ﬂuorinated a-
amino acid derivatives, acyclic ﬂuorinated b-amino acid derivatives,
other acyclic ﬂuorinated amino acid derivatives, cyclic ﬂuorinated
a-amino acid derivatives, cyclic ﬂuorinated b-amino acid de-
rivatives and, ﬁnally, other cyclic ﬂuorinated amino acid
derivatives.1.2. Evolution of sulfur ﬂuoride deoxyﬂuorinating reagents
The history of sulfur ﬂuoride deoxyﬂuorinating reagents started
in 1958 with the discovery that SF4, the parent compound of this
reagent family is capable of transforming carbonyl and carboxyl
groups into diﬂuoromethylene and triﬂuoromethyl groups,
respectively [26]. Furthermore, in 1960, its ability to exchange a
hydroxy group to ﬂuorine was also reported [27]. Originally, these
Scheme 16. Synthesis of substituted 3-ﬂuorophenylalanines from a-hydroxy-b-amino acid derivatives. All isolated compounds have dr> 99:1 [54].
Scheme 17. Synthesis of (2R,3R)-3-ﬂuoroaspartic acid [56].
A.M. Remete et al. / Tetrahedron 74 (2018) 6367e6418 6375transformations had to be performed in an autoclave at elevated
temperature under (autogenous) pressure. However, after the dis-
covery that HF catalyzes the CO2H/CF3 transformation [27]
through generation of reactive SF3þ cations, it soon became clear
that, in the presence of substantial amounts of HF, carbonyl and
carboxyl groups can also be transformed even at room temperature
[28]. In 1975 an improved version was reported using liquid HF
(also known as anhydrous HF or aHF) as solvent. This new system
has temperature-dependent chemoselectivity: at low temperatures
(e.g. 78 C), only OH/F exchange occurs [29], while at and below
room temperature, carbonyl and carboxyl groups are also trans-
formed into CF2 and CF3 groups [2]. The mechanisms of these
transformations are shown on Scheme 4 [2,30]. Unfortunately,
because SF4 is a toxic and corrosive gas under standard conditions,
it is difﬁcult to handle. This fact together with the specializedequipment requirements of the above protocols (autoclave or ﬂu-
oropolymer vessel) [2,3] generated intensive research for better
alternatives.
The next generation of deoxyﬂuorinating reagents was dia-
lkylaminosulfur triﬂuorides. Their ability to perform C]O/ CF2
and OH/ F transformations were reported in 1973 [31] and 1975
[32], respectively. In contrast with SF4, these new reagents do not
require elevated temperatures to succeed with these reactions.
Namely, OH/F exchange works even at 78 C, and carbon-
yl/diﬂuoromethylene transformations can usually be performed
at room temperature, although in the case of some substrates,
temperatures up to 80e85 C are required [2,32]. Their handling is
also easier: they are liquid at room temperature and can be used in
ordinary glassware [2,31]. These advantageous features resulted in
the widespread use of the easily accessible diethylaminosulfur
Scheme 18. Synthesis of 3-ﬂuoro-N-methyl-D-aspartic acid stereoisomers [57].
Scheme 19. Synthesis of (2S,4S)-5-ﬂuoroleucine [58,59].
A.M. Remete et al. / Tetrahedron 74 (2018) 6367e64186376triﬂuoride or DAST for deoxyﬂuorination [33]. Unfortunately, DAST
is thermally unstable: heating above ~90 C results in explosion
[33,34]. This not only greatly limits large-scale applications of DAST,
but also makes it unsuited for carboxyl/triﬂuoromethyl trans-
formations, which require prolonged heating close to the decom-
position temperature of the reagent [35].In order to found better reagents, thermal stability of dia-
lkylaminosulfur triﬂuorides was studied in 1989 with the ﬁnding
that their decomposition occurs in two steps. The ﬁrst step is a slow
disproportionation of R2NSF3 to SF4 and (R2N)2SF2 at approximately
90 C. The resulting bis(dialkylamino)sulfur diﬂuorides are explo-
sive, and when their concentration is substantially high, they
Scheme 20. Synthesis of 4-ﬂuoroleucine derivatives with CeH oxidation followed by deoxyﬂuorination [60].
Scheme 21. Synthesis of protected 3-ﬂuorovaline with CeH oxidation followed by deoxyﬂuorination [60].
A.M. Remete et al. / Tetrahedron 74 (2018) 6367e6418 6377trigger explosion of the whole mixture. This is the reason why
higher rates of heating give slightly higher detonation tempera-
tures. Changing the alkyl groups had no effect on the temperature
of disproportionation, but greatly inﬂuenced its rate. R2NSF3 com-
pounds derived from 6-membered cyclic amines (piperidine and, in
particular, morpholine) showed increased thermal stability leading
to the realization that long-known morpholinosulfur triﬂuoride
(Morph-DAST or MOST) is a safer alternative to DAST [33]. In 1999,
Deoxoﬂuor [bis(2-methoxyethyl)aminosulfur triﬂuoride] an even
safer new reagent was developed by further research. Its decom-
position is not only much slower compared to that of DAST, but also
produces less heat making Deoxoﬂuor more suited for use on
larger, practical scales. For example, in contrast with DAST, it can
safely transform the carboxyl group into a CF3 moiety. However, the
process requires heating the acyl ﬂuoride at 85e90 C in Deoxoﬂuor
as solvent for prolonged times. The reason of this enhanced thermal
stability is coordination of an ether oxygen atom of the side chain to
the electron-deﬁcient sulfur center, which results in kinetic stabi-
lization [34].
Despite these developments, R2NSF3 reagents still have some
disadvantages. For example, all of them are moisture sensitive
similar to SF4. It is alsoworth to note that their synthesis is easy (SF4
is reacted with dialkylaminotrimethylsilane in an apolar organic
solvent), but the crude product has to be puriﬁed through vacuum
distillation. It is not only dangerous requiring extensive safety
measures, but also increases the ﬁnal cost of the reagent [36].
Mechanisms of deoxyﬂuorinations with dialkylaminosulfurtriﬂuorides are shown on Scheme 5 [2,36,37].
The next leap forward was done in 2009 with the discovery that
aminodiﬂuorosulﬁnium salts effectively induce deoxyﬂuorination
of alcohols and oxo compounds in the presence of an exogenous
ﬂuoride source [38]. Interestingly, although these compounds were
known since 1977, their reactivity was previously not studied
thoroughly [38,39]. Mainly their reactions with silylamines were
researched [39], and there was only a single article reporting their
use for deoxyﬂuorination [40]. The initial 2009 study was followed
by a more detailed article in 2010, and two representatives,
diethylaminodiﬂuorosulﬁnium tetraﬂuoroborate (XtalFluor-E) and
morpholinodiﬂuorosulﬁnium tetraﬂuoroborate (XtalFluor-M),
became commercially available. It was shown that in contrast with
previous deoxyﬂuorinating reagents, XtalFluors normally do not
liberate ﬂuoride ion when they transform the hydroxy group into a
good leaving group. This explains the need for an exogenous ﬂuo-
ride source, although an appropriate base like DBU can also induce
the release of ﬂuoride ion and completion of the reaction when
alcohols are deoxyﬂuorinated.
Compared to DAST and Deoxoﬂuor, XtalFluor reagents have
multiple advantages. They are easy-to-handle solids with lower
moisture sensitivity. For example, they can be handled under open
atmosphere for a short time. Their selectivity is higher, because less
elimination side products are formed. Their decomposition tem-
perature is much higher making their use safer, even though the
heat they produce during the process is comparable to that liber-
ating with the use of Deoxoﬂuor. From a manufacturing point of
Scheme 22. Synthesis of (S)-a-ﬂuoromethyltryptophan and (S)-a-ﬂuoromethyl-5-hydroxytryptophan. Their enantiomers were synthesized analogously from D-96a,b [62].
Scheme 23. Synthesis of N-methyl-5,5,5-triﬂuoro-L-norvaline derivatives [63]. The yield of the ﬁrst step was not reported; a yield of 85% was found with aspartic acid [66].
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Scheme 24. Synthesis of 5-bromo-4,4-diﬂuoro- and 4,4-diﬂuoro-L-norvaline derivatives [64].
N CO2EtPh
Ph
117
TsO OBn
118
tBuOK, DMSO
RT, overnight
CO2EtN
OBn
Ph
Ph
(±)-119
1. 1M HCl(aq)
EtOH, RT, 2 h
2. PhthO, neat
45 °C, 30 min
CO2RNPth
OBn
(±)-120a: R = Et
(21% from 117)
H2, Pd/C
EtOAc, RT, 4 h
CO2RNPth
OH
(±)-121a (86%)
Dess-Martin
periodinane (DMP)
CH2Cl2, RT, 2 h
CO2RNPth
O
(±)-123a (75%)
Deoxofluor, CH2Cl2
RT, 18.5 h
CO2EtNPth
F
(±)-122 (21%)
CH2Cl2
RT
CO2RNPth
CHF2
(±)-124
DAST, 3 h: 25%
MOST, 3 h: 35%
Deoxofluor, 4 h: 38%
6 M HCl(aq), AcOH
130 °C, overnight
HO2C NH3Cl
F2HC
(±)-125 (89%)
Scheme 25. Synthesis of racemic 5-ﬂuoro- and 5,5-diﬂuoronorvaline derivatives. Deprotection of (±)-122 was unsuccessful [65].
Scheme 26. Synthesis of (R)-5,5-diﬂuoronorvaline hydrochloride [65].
A.M. Remete et al. / Tetrahedron 74 (2018) 6367e6418 6379view, they can be synthesized in high quality and yield from crude
DAST or MOST eliminating the need for costly and dangerous vac-
uum distillation of these dialkylaminosulfur triﬂuorides. Instead,because XtalFluors crystallize out of the reaction mixture, a simple
ﬁltration is satisfactory for their isolation. Although they require
DBU or Et3N$3HF in excess for successful deoxyﬂuorination, these
Scheme 27. Synthesis of N-Fmoc-protected (S,E)-2-amino-5-ﬂuoropent-3-enoic acid [67].
Scheme 28. Synthesis of 4-polyﬂuorinated L-2-aminobutanoic acid derivatives [63,66].
A.M. Remete et al. / Tetrahedron 74 (2018) 6367e64186380reagents are cheap and Et3N$3HF can be handled in standard bo-
rosilicate glassware up to 150 C without etching. However, they
cannot perform the CO2H/CF3 transformation; rather, carboxylic
acids are converted only to acyl ﬂuorides. Mechanisms of deoxy-
ﬂuorinations with XtalFluor reagents are shown on Scheme 6 [36].
In 2010, the discovery of 4-tert-butyl-2,6-dimethylphenylsulfur
triﬂuoride (FluoLead) as a new ﬂuorinating reagent was reported
[41]. Similar to aminodiﬂuorosulﬁnium salts, arylsulfur triﬂuorides
were known for a long time, but their deoxyﬂuorinatingcapabilities were largely unexplored. A report of their synthesis and
properties from 1960 already mentioned that PhSF3 can transform
benzaldehyde into benzal ﬂuoride [42], and a subsequent article in
1962 from the same author showed that it can be used for C]O/
CF2 and CO2H/CF3 transformations in amanner similar to SF4 [43].
However, after the discovery of DAST, arylsulfur triﬂuorides were
mostly ignored with the exception of a report in 1981 where PhSF3
was used to ﬂuorinate cholesterol [41,44]. More importantly, the
search for better, thermally more stable ﬂuorinating reagents
Scheme 29. Synthesis of Met analogue 5,5-diﬂuoro-L-norleucine [68].
A.M. Remete et al. / Tetrahedron 74 (2018) 6367e6418 6381resulted in re-evaluation of this family of compounds. It was
anticipated that the higher strength of the CeS bond compared to
that of the NeS bond makes disproportionation, which is the ﬁrst
step during thermal decomposition of dialkylaminosulfur tri-
ﬂuorides, more difﬁcult. Experiments to carry out deoxyﬂuorina-
tion of benzyl alcohol showed that ortho substitution of the reagent
suppresses ether formation. The increased steric hindrance makes
the reaction of the reactive intermedier with another alcohol
molecule difﬁcult. Furthermore, steric shielding of the arene ring
suppressed polymerization and para substitution with the tert-
butyl group increased the yield of the ﬂuorinated product. 4-tert-
Butyl-2,6-dimethylphenylsulfur triﬂuoride, one of the most effec-
tive ﬂuorinating agents commercialized under the name FluoLead,
also showed remarkable resistance to hydrolysis. This new reagent
is an easy-to-handle solid, can be used under open atmosphere and
has a thermal stability comparable to that of XtalFluor reagents. It
can transform OH into F and C]O into CF2 at or slightly below room
temperature. Note that in the second transformation, excess pyri-
dine/9HF is needed. In addition, it can even transform CO2H into
CF3 at elevated temperature: with excess pyridine/9HF a temper-
ature of 50 C is sufﬁcient, whereas 100 C is required with a stoi-
chiometric amount of reagent. Mechanisms of deoxyﬂuorinations
with FluoLead are shown on Scheme 7 [41].
To sum up, deoxyﬂuorinating reagents transform the oxygen
into a good leaving group, which is subsequently displaced by
ﬂuoride [2]. With the exception of XtalFluor reagents, the necessary
ﬂuoride ion is generated during the creation of the good leaving
group [36]. In the case of alcohol deoxyﬂuorinations, the stereo-
chemical outcome is also important: most reactions proceed
through an SN2 pathway [2]. Substrates capable of producing sta-
bilized carbocations, in turn, favor SN1 [3] and reactions with SF4 in
aHF have a pronounced SN1 character [29].2. Synthesis of ﬂuorinated amino acids through late-stage
ﬂuorination
2.1. Synthesis of acyclic a-amino acid derivatives
L-Tyrosine derivatives with an attached ﬂuorinated moiety were
synthesized through late-stage deoxyﬂuorination as cold reference
compounds of their 18F-containing counterparts, which are po-
tential PET tracers.
Malik et al. synthesized N-[(benzyloxy)carbonyl]-O-[2-ﬂuoro-3-
(2-nitro-1H-imidazole-1-yl)propyl]tyrosine methyl ester 19
(Scheme 8) [45], Franck et al. prepared 3-ﬂuorocyclobutyl-L-tyro-
sine (FCBT, 24, Scheme 9) [46], while Chiotellis et al. reported the
synthesis of O-2((2-ﬂuoroethyl)methylamino)ethyl L-tyrosine
(FEMAET, 29, Scheme 10) [47]. Their common synthetic strategy
included alkylation of N-protected L-Tyr ester, liberation of a hy-
droxy group, and then deoxyﬂuorination usually followed by
deprotection.
Another common aim of synthesizing ﬂuorine-containing Tyr
derivatives was to obtain suicidal probes for protein tyrosine
phosphatases. As precursors for the desired probe molecules, Shen
and co-workers prepared CHF2-containing phosphotyrosine
analogue 33 (Scheme 11) [48], Kalesh et al. synthesized CH2F-
containing analogue 38 (Scheme 12) [49], while Huang et al. pre-
pared ﬂuorinated dipeptide 42 (Scheme 13) [50].
3-Fluoroalanine derivatives can be prepared from easily avail-
able serine derivatives. Hoveyda et al. protected Ser residue as an
oxazolidinone derivative and synthesized both enantiomers of 3-
ﬂuoroalanine and N-methyl-3-ﬂuoroalanine derivatives, which
were used for solution-phase peptide synthesis successfully [51].
Voyer and co-workers modiﬁed this synthetic pathway to obtain a
3-ﬂuoroalanine derivative applicable to solid-phase peptide syn-
thesis (Scheme 14) [52].
Ross and co-workers synthesized N-propargyl-3-ﬂuoro-L-
Scheme 30. Synthesis of diﬂuorinated 2-aminonon-8-enoic acid and 2-aminodec-9-enoic acid derivatives [69].
Scheme 31. Improved synthesis of (2S,3R,6S)-3-ﬂuoro-2,6-diaminopimelic acid [71].
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Scheme 32. Synthesis of 3-ﬂuoro-2-aminoacrylic acid derivatives [72].
Scheme 33. Synthesis of ﬂuorinated L-cyclohexylglycine derivative 175 [74].
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thetic group. The nitrogen was protected with a 2,4-
dimethoxybenzyl group (Scheme 15) [53].
Davies and co-workers published the synthesis of 3-
ﬂuorophenylalanine derivatives from a-hydroxy-b-amino acid de-
rivatives. XtalFluor-E transformed the OH group to a good leaving
group, which was displaced by the neighboring amino group
creating an aziridinium ion. The latter thenwas opened stereo- and
regioselectively by the ﬂuoride ion. Deprotection had to be ach-
ieved with BrO3 because hydrogenolysis resulted in deﬂuorination
(Scheme 16) [54].
Strauss and co-workers used the method of Charvillon et al. [55]
starting from L-diethyl tartrate with improved multiple synthetic
steps. Most signiﬁcantly, epoxide opening with Bn2NH afforded
(2R,3R)-3-ﬂuoroaspartic acid 67 (Scheme 17), which was used to
study aspartate decarboxylases. Note that deoxyﬂuorination of the
b-hydroxy a-amino acid intermediate took place with retention ofconﬁguration instead of the usual inversion resulting from the
involvement of an aziridinium ion intermediate [56].
O'Hagan and co-workers synthesized 3-ﬂuoro-N-methyl-D-
aspartic acid stereoisomers in a similar way (Scheme 18). Unfor-
tunately, separation of aminoalcohols 74 and 75 could not be
accomplished; therefore, their mixture was reacted further with
Deoxoﬂuor. Hydrogenolysis of that compound resulted in one
enantiomer of erythro-71, but its absolute conﬁguration wasn't
determined. However, the use of (R)-73 instead of its enantiomer,
enabled the synthesis of enantiomeric erythro-71 in an analogous
way [57].
In order to study proteins, Young and co-workers synthesized
(2S,4S)-5-ﬂuoroleucine from protected pyroglutamic acid 78
(Scheme 19). Because attempts to ﬂuorinate alcohol 82 resulted in
cyclization by nucleophilic attack of the carbamate nitrogen,
introduction of a second Boc group to nitrogen was necessary.
Interestingly, this was only possible after protecting the OH group
Scheme 34. Synthesis of 1,2,3-triazole-containing amino acids 180a-c [75].
Scheme 35. Synthesis of a self-immobilizing ﬂuorogenic phosphotyrosine mimic [76].
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Scheme 36. Synthesis of a ﬂuorinated NMDA receptor antagonist with preference for GluN2A [77].
Scheme 37. Synthesis of a ﬂuorinated adamantylglycine DPP-IV inhibitor [78].
Scheme 38. Synthesis of a-ﬂuoro-b-alanine derivatives from N,N-dibenzyl-serine ester [80].
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Scheme 39. Synthesis of ﬂuorinated b-amino acid derivatives from protected Phe hydroxamate [81].
Scheme 40. Synthesis of ﬂuorinated b-amino acid derivative 317 from (R)-2,3-O-isopropylideneglyceraldehyde [82].
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Osberger et al. developed a versatile CeH oxidation of amino
acid derivatives inspired by non-ribosomal peptide synthetases.
H2O2 is used as oxidant and iron(II)-complex 86 or its enantiomer
as catalyst. Oxidation of protected Leu derivative 87 and Leu-
containing peptide 90 derivatized at their tertiary carbon and
subsequent deoxyﬂuorination gave 4-ﬂuoro-L-leucine containing89 and 92 (Scheme 20). Similarly, treatment of protected Val de-
rivative 93 gave N-nosyl-3-ﬂuoro-L-valine tert-butyl ester (Scheme
21) [60].
During his research to improve radiosynthesis of 4-[18F]-ﬂuoro-
L-arginine and obtain isotopic reference substances, Dittmar re-
ported the synthesis of a bislactim ether derivative ofN-dibenzyl-4-
ﬂuoro-L-ornithine. The ﬂuorination step produced a 1:1 mixture of
Scheme 41. Synthesis of open chain a-ﬂuorinated b-amino acids [83e85].
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failed [61].
In the biosynthesis of serotonine and dopamine, the ﬁnal step is
performed by aromatic L-amino acid decarboxylase (AADC).
Because a common feature of carcinoid tumors is overproduction of
serotonine, inhibition of AADC gained considerable interest. For
this reason, Zembower et al. prepared the enantiomers of a-ﬂuo-
romethyltryptophan and a-ﬂuoromethyl-5-hydroxytryptophan
(Scheme 22). Tryptophan hydroxylase was shown to transform
(S)-103a to (S)-103b, which is an irreversible inhibitor of AADC, but
(R)-103a is not hydroxylated and (R)-103b does not inhibit AADC
[62].
Burger and co-workers used N-methylglutamic acid as a starting
material. Simultaneous protection/activation of the neighboring
amino and carboxyl groups with hexaﬂuoroacetone followed by
transformation of the free g-carboxylic acid group to CF3 by SF4resulted in reactive amino acid derivative 106, which readily reacts
with nucleophiles (Scheme 23) [63]. In a later publication, they
converted hexaﬂuoroacetone-protected aspartic acid into acid
chloride, which was transformed into bromoketon 111. Deoxy-
ﬂuorination of 111 gave bromo-ﬂuoro compound 112 then its
debromination provided 113. Similar to 106, 112 and 113 readily
react with various nucleophiles (Scheme 24) [64]. Ulbrich et al.
deoxyﬂuorinated N-phthaloylated 5-hydroxy-2-amino- and 5-oxo-
2-aminopentanoic esters to obtain protected 5-ﬂuoro- and 5,5-
diﬂuoronorvaline, but deprotection succeed only with 5,5-
diﬂuoro derivatives (Scheme 25-26) [65].
Lantibiotics are a group of peptide antibiotics synthesized in a
ribosomal and modiﬁed in a post-translational way. After the
enzyme system responsible for the posttranslational modiﬁcations
was reconstructed in vitro and showed high substrate promiscuity,
van der Donk and co-workers made multiple nonproteinogenic
Scheme 42. Synthesis of racemic N-benzoyl-2-ﬂuoromethyl-syn-phenylisoserine [86].
Scheme 43. Synthesis of diﬂuoromethyl-containing b-amino acid derivative 245 [87,88].
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(S,E)-2-amino-5-ﬂuoropent-3-enoic acid 132 (Scheme 27). Starting
from D-Garner aldehyde, the carbon backbone was constructed
ﬁrst, followed by deoxyﬂuorination, protecting group exchange and
oxidation [67].
The Burger group synthesized L-4,4-diﬂuoro-2-aminobutanoic
acid and N-methyl-L-4,4,4-triﬂuoro-2-aminobutanoic acid from
hexaﬂuoroacetone-protected aspartic acid derivatives (Scheme 28).
In the ﬁrst case, the free b-carboxyl group was reduced to aldehyde,
which underwent deoxyﬂuorination, followed by hydrolysis to
obtain ﬂuoro analogue of natural antibiotic L-armentomycin [66]. In
the second case, the free b-carboxyl group was converted into a CF3
group followed by reaction with different nucleophiles [63].Osada and co-workers prepared 5,5-diﬂuoro-L-norleucine (5,5-
diﬂuoro-L-2-aminohexanoic acid) as an oxidation-resistant methi-
onine analogue from L-glutamic acid or D-serine (Scheme 29) [68].
In the latter synthetic route, an appropriate acetonide-protected 2-
aminoalcohol was prepared, which underwent deoxyﬂuorination,
acetonide removal and oxidation of CH2OH to CO2H. Finally, the N-
Boc group was replaced with N-Fmoc to facilitate incorporation
into peptides by solid-support peptide synthesis.
Ring opening of N-Boc lactams with homoallylmagnesium
bromide and subsequent deoxyﬂuorination with Deoxoﬂuor per-
formed byNair et al. delivered protected derivatives of 4,4-diﬂuoro-
L-2-aminonon-8-enoic acid and 5,5-diﬂuoro-L-2-aminodec-9-enoic
acid. The use of DAST gave lower yields (40% for 155a and 50% for
Scheme 44. Synthesis of enantiomers of diﬂuoromethyl-containing b-lactams 250 and 251 [89,91].
Scheme 45. Synthesis of diﬂuoromethyl-containing b-lactams (þ)-250 and (þ)-251 [90,92]. Enantioselective syntheses of (þ)-249 and (¡)-249 were reported in [92] and [91],
respectively.
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were transformed into diﬂuorinated macrocycles exerting biolog-
ical activity against hepatitis C virus NS3 serine protease. In the
synthesis of dipeptide 158, deoxyﬂuorination of dipeptide 156 gave
a better overall yield. Even tripeptide 157 can be deoxyﬂuorinated
efﬁciently (Scheme 30) [69].
Sutherland et al. synthesized (2S,3R,6S)-3-ﬂuoro-2,6-
diaminopimelic acid by an improved version of the method of
Gelb et al. [70] A different protected glutarate semialdehyde was
used to construct bislactim ether 162, and by adding trace amountsof water during deoxyﬂuorination, dehydration was suppressed
successfully (Scheme 31) [71].
To increase the Michael acceptor properties of dehydroalanine,
an unusual amino acid present in a large number of natural prod-
ucts, Zhou and van der Donk developed a procedure to access both
geometrical isomers of its 3-ﬂuorinated derivative. From N-Fmoc-
serine, protected S-aryl-cysteine (±)-166 was prepared and then
oxidized to sulfoxide mixture 167. Fluoro-Pummerer rearrange-
ment gave ﬂuorinated cystein derivative 168, which was trans-
formed into a separable 1:1 mixture of (Z)- and (E)-3-ﬂuoro-2-
Scheme 46. Synthesis of 2,3-diﬂuoro-GABA stereoisomers [87,88,93]. Synthesis of (2R,3R)-243 is shown on Scheme 43. Synthesis of (2S,3S)-254 and (2S,3R)-254 was achieved
analogously to the synthesis of their enantiomers, with a single difference in the ﬁrst step (see text).
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sulfenic acid. (±)-166 was incorporated into dipeptide (±)-170,
which under similar conditions gave analogous products (Scheme
32) [72]. However, Zhou et al. reported that oxidation and subse-
quent ﬂuorination of a tripeptide containing L-166 provided a low
yield of the desired product because of a cyclization side reaction
[73].
Ishikawa and co-workers synthesized a ﬂuorinated L-cyclo-
hexylglycine derivative, which served as a building block for an
inhibitor of apoptosis protein (IAP) antagonists (Scheme 33) [74].
Yook et al. prepared multiple 1,2,3-triazole-containing ﬂuori-
nated amino acids as cold reference compounds for their PET tracer
candidates (Scheme 34). Click reaction of propargyl alcohol and
azido-amino acids constructed the triazol ring followed by deoxy-
ﬂuorination and protecting group removal [75].
Yao and co-workers synthesized a self-immobilizing ﬂuorogenic
phosphotyrosine mimic, which was used to prepare peptidic
probes for protein tyrosine phosphatases through solid-state pep-
tide synthesis (Scheme 35). The coumarin part is responsible for the
ﬂuorescence, and upon dephosphorylation, the ﬂuoromethyl moi-
ety enables formation of a reactive quinone methide, which at-
taches itself covalently to nearby proteins [76].
During their research towards NMDA receptor antagonists withpreference for GluN2A over GluN2B subunits, Lind et al. synthe-
sized dihydropyrazole-containing ﬂuorinated amino acid 194
exhibiting a 15-fold preference for GluN2A (Scheme 36) [77].
Augeri et al. made a large number of L-cis-4,5-
methanoprolinenitrile dipeptidyl peptidase IV (DPP-IV) inhibitors
linked to adamantylglycine including ﬂuorinated derivative 201
(Scheme 37). However, the best results were achieved with a non-
ﬂuorinated derivative named saxagliptin, which contained an OH
group rather than a F in 201 [78].2.2. Synthesis of acyclic ﬂuorinated b-amino acid derivatives
Dervan and co-workers slightly modiﬁed the conditions re-
ported by Gani et al. [79] to obtain protected b-alanine derivative
206 from N,N-dibenzyl-serine methyl ester 202 (Scheme 38) [80].
The reaction proceeds through an aziridinium ion intermediate,
which is regio- and stereoselectively opened by the ﬂuoride ion.
Note that ring opening of 203-like aziridinium ions with an addi-
tional Ph group results in opposite regioselectivity (see Section 2.1,
Scheme 16) [54].
Fluorinated b-amino acid analogues of phenylalanine made by
Ohba et al. were used to obtain a-chymotrypsin inhibitors. Pro-
tected L-Phe hydroxamate 207 was reduced to the corresponding
Scheme 47. Improved synthesis of (2R,3S)-254 and (2S,3S)-254 [94].
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tion. The free OH group was deoxyﬂuorinated either at this stage to
give syn- and anti-211, or after oxidation to carbonyl group to give
213. N-Cbz of these compounds was then changed to N-Ac (Scheme
39) [81].
As a part of their research program towards synthesizing
enantiomerically pure b-amino acids, Fokina and co-workers pre-
pared compound 223 from readily available (R)-2,3-O-iso-
propylideneglyceraldehyde. Grignard reaction created an OH
group, which was substituted by a phthalimido group. Acetonide
removal and subsequent protection of the liberated primary OH
group gave two diastereomeric alcohols. The major diastereomer
was oxidized to the corresponding ketone, which was subjected to
deoxyﬂuorination. Removal of the O-protective group andsubsequent oxidation gave b-amino acid derivative 223 (Scheme
40) [82].
Seebach and co-workers reported the synthesis of varied a-
ﬂuorinated b-amino acids from N,N-dibenzyl-a-amino aldehydes
derived from natural amino acids L-Thr, L-Val and L-Leu [83]. These
were incorporated into b-peptides to study their effects on con-
formations. Detailed description of these transformations and their
improvements (Scheme 41) were published later in two different
articles: one for compounds derived from L-Thr [84] and another for
the other amino acids [85]. Originally, chain extension of the
starting aldehydes was accomplished through simple trans-
cyanohydrination (see [81]) and subsequent nitrile hydrolysis.
Finally, the resulting a-hydroxy-b-amino ester diastereomers were
usually separated (except for the Swern oxidation) [83]. However,
Scheme 48. Synthesis of (±)-3-triﬂuoromethyl-GABA and (±)-N-benzyl-b-diﬂuoromethyl-g-butyrolacton [95].
Scheme 49. Synthesis of 2-ﬂuoro-GABA hydrochloride. Conﬁgurations were not
deﬁned [96].
Scheme 50. Synthesis of 2-ﬂuoromethyl-3-
A.M. Remete et al. / Tetrahedron 74 (2018) 6367e64186392stereoselective cyanohydrination enabled the synthesis of pure
diastereomers of 226. Fluorination of 226a-c diastereomers pro-
ceeds through an aziridinium ion intermediate (see [54]). Ring
opening of aziridinium ions derived from (2S,3S)-226a-c is highly
regioselective because an SN2-assisting conformation of the ester
group is possible. Steric hindrance in aziridinium ions derived from
(2R,3S)-226a-c, in turn, results in decreased regioselectivity except
for (2R,3S)-226b, where the iPr substituent possibly hinders an
alternative ring opening [85].
During their study to obtain analogues of N-benzoyl-syn-phe-
nylisoserine (the side chain of paclitaxel), Galeazzi et al. synthe-
sized ﬂuoromethyl analogue (±)-237. Base-promotedaminobutyric acid derivative 283 [97].
Scheme 51. Synthesis of (2S,3R,4S)eN-phthaloyl-2,3,4-triﬂuoro-5-aminopentanoic acid [98].
Scheme 52. Synthesis of (2S,3S,4R)-N-phthaloyl-2,3,4-triﬂuoro-5-aminopentanoic acid. (þ)-287 was obtained analogously to (¡)-287 using L-62 instead of D-62 [98].
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Scheme 53. Synthesis of (2S,4S)-4-ﬂuoroproline derivatives 299f-g suitable for solid-phase peptide synthesis [99,102,104].
Scheme 54. Synthesis of (2S,4R)-4-ﬂuoroproline derivatives 301f-g suitable for solid-phase peptide synthesis [99,104,106].
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alcohol (±)-230 to benzoyl isocyanate, followed by iodocyclization
gave 4,5-dihydro-1,3-oxazole derivative (±)-233 as a single prod-
uct. Its iodine atom was substituted with OAc, which was hydro-
lyzed to OH, accompanied with transesteriﬁcation. The obtained
(±)-235 was deoxyﬂuorinated and hydrolysis of the heterocycle
resulted in ﬂuorinated b-amino acid derivative (±)-237 (Scheme
42) [86].
During their attempts to prepare a,b-diﬂuoro-g-amino acids
from cinnamyl bromide in a stereoselective manner and charac-
terize their conformations, Hunter et al. observed considerable
phenyl group migration during ﬂuorination of a ﬂuorohydrin [87].
As reported in a subsequent article, oxidation of the phenyl group of
this undesired product resulted in a diﬂuoromethyl-containing b-amino acid derivate (Scheme 43) [88].
Ojima and co-workers used kinetic resolution to obtain both
enantiomers of 4-alkenyl-b-lactam 249, which were transformed
into enantiomers of diﬂuoromethyl-containing b-lactams 250 and
251 through alkene cleavage and deoxyﬂuorination of the aldehyde
products (Scheme 44). These were used to obtain novel ﬂuorine-
containing taxoids and ß-amino acid derivatives [89]. Interest-
ingly, transformations of (þ)-250 and (¡)-250 have different yields.
Previously, Ojima et al. reported slightly different yields and con-
ditions for the transformation of (þ)-249 (Scheme 45) [90].2.3. Synthesis of other acyclic ﬂuorinated amino acid derivatives
A common case during the synthesis of g-amino acid derivatives
Scheme 55. Synthesis of all N-acetyl-4-ﬂuoroproline methyl esters and 4-ﬂuoroglutamic acid stereoisomers [107].
Scheme 56. Synthetic use of (2S,4S)-4-ﬂuoropyrrolidine-2-carbonyl ﬂuorides [108].
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derivatives of GABA or g-aminobutyric acid. Hunter et al. reported
both the synthesis and the conformational characterization of
stereoisomeric 2,3-diﬂuoro-GABA derivatives (2R,3R)-254 and
(2R,3S)-254 starting from cinnamyl bromide 238 (Scheme 46) [87].
In a follow-up article, these and their enantiomers obtained anal-
ogously (AD-mix b was used for the asymmetric dihydroxylationinstead of AD-mix a resulting in the enantiomer of 239) were
deprotected to the four stereoisomeric 2,3-diﬂuoro-GABA hydro-
chlorides. Receptor binding abilities of GABAA, GABAB and GABAC
were also studied (Scheme 46) [93]. Hunter and co-workers later
improved the synthetic pathway towards (2R,3S)-254 and (2S,3S)-
254 (Scheme 47) [94].
With the aim of preparing ﬂuorinated GABA analogues, Gerus
and co-workers transformed 1-benzyl-5-oxopyrrolidine-3-
carboxylic acid (±)-266 into racemic g-lactams (±)-269 and
(±)-270. Transformation of the free carboxyl or aldehyde group to
ﬂuorinated methyl groups was not problematic, but removal of the
N-benzyl group through hydrogenolysis was unsuccessful and
lactam hydrolysis under mild conditions failed. However, (±)-269
underwent degradation and HF loss under forcing conditions, while
(±)-270 was hydrolyzed successfully affording a low product yield.
Hydrogenolysis of the resulting (±)-271 gave free (±)-3-
triﬂuoromethyl-GABA (Scheme 48) [95].
Ma et al. synthesized 2-ﬂuoro-GABA (Scheme 49) and then
incorporated it into a docetaxel derivative after N-methylation.
However, stereochemistry of the asymmetric carbons was not
deﬁned [96].
Scheme 57. Synthesis of (2S,4S)eN-(4-iodobenzoyl)-4-ﬂuoroproline methyl ester 299q and its 4-iodobenzyl-containing analogue 299r [109].
Scheme 58. Synthesis of (2S,4R)-4-ﬂuoroproline from 110 available from (S)-aspartic acid (Scheme 24). Enantiomer of 301n can be synthesized analogously from (R)-aspartic acid
[110].
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which can be incorporated into proteins as a reporter group, Young
and co-workers synthesized g-amino acid derivative 283 as an in-
termediate. After diastereoselective alkylation of g-lactam 278
(obtained from (S)-pyroglutamic acid 277), oxidative cleavage of
the incorporated unsaturated moiety and reduction led to
hydroxymethyl-containing 281, which was subjected to ﬂuorina-
tion and subsequent ring opening (Scheme 50) [97].
Cheerlavancha et al. developed a multi-step procedure to access
(2S,3R,4S)- and (2S,3S,4R)-isomers of N-phthaloyl-2,3,4-triﬂuoro-5-
aminopentanoic acid. Enantiomers of 286 were constructed
through cross metathesis and subjected to asymmetric epoxida-
tion. Three consecutive nucleophilic ﬂuorination steps gave inter-
mediate 291. Finally, phenyl groups were oxidized to CO2H groups
(Scheme 51-52). The obtained N-phthaloyl-2,3,4-triﬂuoro-5-
aminopentanoic acids have the same backbone length as a dipep-
tide made of a-amino acids, but their conformations are greatly
affected by ﬂuorine atoms. NMR data suggest that (2S,3R,4S)-293
has an extended geometry, while (2S,3S,4R)-293 prefers a bent
shape [98].2.4. Synthesis of cyclic ﬂuorinated a-amino acid derivatives
For various reasons, many research groups synthesized (2S,4S)-
4-ﬂuoroproline derivatives from the easily available (2S,4R)-4-
hydroxyproline (Table 1). With the aim of using in solid-phase
peptide synthesis, 299a prepared by Dugave and co-workers was
converted into carboxylic acids 299f-g having suitable protection
(Scheme 53) [99]. Ji et al. synthesized and then transformed 299a
into DPP IV inhibitors containing 4-ﬂuoropyrrolidine-2-carbonitrile
[100]. 299a was also prepared by Hunter and co-workers and then
hydrolyzed into (2S,4S)-4-ﬂuoroproline hydrochloride, which was
evaluated as an enantioselective catalyst [101]. Fields and co-
workers made 299b (and 299f, see Scheme 53), which were used
as building blocks for collagen-mimicking peptides [102], whereas
Hodges et al. synthesized 299c for the same reason [103]. In order
to facilitate access to Boc- and Fmoc-protected (2S,4S)-4-
ﬂuoroprolines, Kobayashi and co-workers synthesized 299d,
where the phenacyl ester moiety is stable during acidolytic Boc
deprotection but can be deprotected with Zn/AcOH without
affecting Boc or Fmoc groups (Scheme 53) [104]. Gichuhi et al. used
Scheme 59. Stereoselective ﬂuorinations of resin-bound peptides containing 4-hydroxy-L-proline. RN¼Ac-Thr(OtBu)-Tyr(OtBu) [111].
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preparation of a 3-ﬂuoro-2-substituted pyrrolidine derivative
[105].
The synthesis of (2S,4R)-4-ﬂuoroproline derivatives from
(2S,4S)-4-hydroxyproline, often obtained from (2S,4R)-4-
hydroxyproline, is a widely-used method (Table 2). Dugave and
co-workers obtained 301a and then converted it into carboxylic
acids 301f-g suitably protected for solid-phase peptide synthesis
(Scheme 54) [99]. Hunter and co-workers also synthesized 301a
and hydrolyzed it into (2S,4R)-4-ﬂuoroproline hydrochloride (2M
HCl, reﬂux, overnight, quantitative), which was evaluated as an
enantioselective catalyst [101]. 301b, synthesized by Fields and co-
workers [102] and 301c, prepared by Hodges et al. [103] were used
as building blocks for collagen-mimicking peptides. In order to
facilitate access to Boc- and Fmoc-protected (2S,4R)-4-
ﬂuoroprolines, Kobayashi and co-workers synthesized phenacyl
ester 301d and transformed it into 301f-g (Scheme 54) [104].
Bhowmick and Fields improved the synthesis of 301g by preparing
it from 301j obtained from 298j (Scheme 54) [106].
Hudlický reported the synthesis of all stereoisomeric N-acetyl-
4-ﬂuoroproline methyl esters. The product compounds were
oxidized to pyroglutamic acid derivatives and then subsequent
hydrolysis afforded all 4-ﬂuoroglutamic acid stereoisomers [107].
While 303 was successfully epimerized at C-4 by Mitsunobureaction, analogous transformation of 298L was unsuccessful. This
was circumvented by oxidation of 298m to 4-ketoproline derivative
307a, which was reduced to N-Cbz-protected cis-4-hydroxy-L-
proline 300m in a diastereoselective manner (Scheme 55) [107].
Singh and Umemoto reported the synthesis of N-protected
(2S,4S)-4-ﬂuoropyrrolidine-2-carbonyl ﬂuorides from N-protected
(2S,4R)-4-hydroxyprolines with FluoLead. In the case of Boc-
protected 298a, addition of a base was necessary to avoid depro-
tection. As shown with Fmoc-protected 298b, pyridine/9HF accel-
erated this process considerably. Interestingly, the reaction of
stereoisomeric 300k was much less effective (Table 3). The ob-
tained carbonyl ﬂuorides are reactive acylating agents used efﬁ-
ciently to produce (2S,4S)-4-ﬂuoroproline derivatives such as
carbonitriles, carboxylates, carboxamides and Weinreb amides in
fewer steps than usual (Scheme 56) [108].
During their study to develop inhibitors and PET tracers for
matrix metalloproteinase (MMP) inhibitors, Kalinin et al. synthe-
sized (2S,4S)eN-(4-iodobenzoyl)-4-ﬂuoroproline methyl ester
299q and its 4-iodobenzyl analogue 299r (Scheme 57), which were
used as starting compounds for Sonogashira coupling [109].
Burger and co-workers synthesized (2S,4R)-4-ﬂuoroproline and
its derivatives from (S)-aspartic acid through diazoketone 110 (see
Section 2.1, Scheme 24). Rh-catalyzed cyclization gave
hexaﬂuoroacetone-protected 4-keto-L-proline 311, which was
Scheme 60. Fluorinations of trans-4-hydroxy-L-proline containing peptides and 4-hydroxyproline derivatives 300p, 298s and 300s [112].
Scheme 61. Synthesis of 4,4-diﬂuoro-L-proline and its derivatives from 311 protected and activated with hexaﬂuoracetone [110].
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hydrolysis resulted in (2S,4R)-4-ﬂuoroproline 301n. (Scheme 58).
The synthesis of (2R,4S)-4-ﬂuoroproline from the enantiomeric (R)-
aspartic acid was accomplished in a similar way [110].
Zondlo and co-workers reported the ﬂuorination of peptides
316a and 316b containing cis- and trans-4-hydroxy-L-proline. N-
Fmoc-trans-4-hydroxy-L-prolinewas incorporated into the growing
peptide chainwith the standard solid-phase synthetic method, and
subsequent tritylation of the OH group allowed protection during
the next coupling steps. After the incorporation of every amino acid
to give 315, the O-trityl group was removed. The resulting 316awas
ﬂuorinated to 317a containing (2S,4S)-4-ﬂuoroproline and then
cleaved from the resin. In the synthesis of (2S,4R)-4-ﬂuoroproline-
containing 318b, 316a was subjected to epimerization byMitsunobu reaction, followed by deoxyﬂuorination and cleavage
from the resin (Scheme 59) [111]. In contrast, Tran et al. reported
ﬂuorination of peptides 319 and 321 containing trans-4-hydroxy-L-
proline giving diastereomeric mixtures. Fluorination of (2S,4S)-4-
hydroxyproline methyl ester hydrochloride 300p and N-Fmoc-
protected methyl esters 298s and 300s also resulted in diastereo-
meric mixtures (Scheme 60), in contrast with the behavior of N-
Fmoc-protected benzyl esters 298b and 300b [102] (see Tables 1e2)
[112].
Filosa et al. studied the allylation of 299a and 301a and syn-
thesized N-Boc-protected (2S,4S)- and (2R,4S)-2-allyl-4-
ﬂuoroproline methyl esters as reference compounds starting from
N-Boc- and O-TBS-protected (2S,4R)- and (2R,4R)-2-allyl-4-
hydroxyproline methyl esters [113].
Scheme 62. Synthesis of 4,4-diﬂuoro-L-proline derivatives 324d-e suitable for solid-phase peptide synthesis and their precursor 324c [99].
Scheme 63. Fluorinations of 4-keto-L-proline-containing resin-bound peptide 326. RN¼Ac-Thr(OtBu)-Tyr(OtBu) [111].
Scheme 64. The original synthetic pathway towards (R)-338 [114].
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Scheme 65. The improved synthetic pathway towards (R)-338 [114].
Scheme 66. Synthesis of 3-ﬂuoro-L-proline derivatives from (2S,3S)-3-hydroxyproline [115].
A.M. Remete et al. / Tetrahedron 74 (2018) 6367e64186400The Burger group transformed ﬂuorinated 4-keto-L-proline de-
rivative 311 to 4,4-diﬂuoro-L-proline derivative 323 and thenreacted it with various nucleophiles (Scheme 61) [110]. In order to
obtain 4,4-diﬂuoro-L-proline derivatives suitable for solid-phase
Scheme 67. Synthesis of (3R,4R)-diﬂuoro-L-proline through the ring expansion of azetidinecarboxylic acid derivative 348 [116].
Scheme 68. Synthesis of enantiomerically pure 3,3-diﬂuoro-L-proline. Resolution of both the mother liquor after removal of L-354 and (±)-354with L-tyrosine hydrazide gave D-359
[117].
A.M. Remete et al. / Tetrahedron 74 (2018) 6367e6418 6401peptide synthesis, Dugave and co-workers transformed (2S,4R)-4-
hydroxyproline derivative 298a to compounds 324d-e through
diﬂuoroproline 324c (Scheme 62) [99].Zondlo and co-workers used their ‘proline editing’ method for
the synthesis of a peptide-containing 4,4-diﬂuoro-L-proline. Com-
pound 316a (see Scheme 59) was oxidized to 326 bearing a 4-
Scheme 69. Synthesis of ﬂuorinated bicyclic proline analogues from ketone 360 [118,119]. Structure of 366 is shown on Scheme 70.
Scheme 70. Detailed synthesis of ﬂuorinated bicyclic proline (±)-368 from ketone (±)-360. Dihydroxylation was used after ﬂuorination to remove the elimination product formed
from (±)-366 [120].
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product from the resin gave peptide 328 containing 4,4-diﬂuoro-L-
proline (Scheme 63) [111].
Rossi et al. improved the synthesis of 4,4-diﬂuoro-3,3-
dimethylproline derivative (R)-338 an intermediate for the syn-
thesis of a HIV protease inhibitor. The original process (Scheme 64)
had multiple drawbacks hindering scale-up. Large quantities of
solvents and reagents were required, productivity was low, the
enzyme used for resolution was no longer commercially available
and the overall yield was a mere 1.5%. Changing the coupling agent
in the ﬁrst step from DCC to EDC gave a water-soluble urea
byproduct eliminating the need for ﬁltration. Surprisingly, the next
step (IrelandeClaisen rearrangement) worked well even without
the original ZnCl2 additive reducing waste issues. The resulting
(±)-332 was resolved through (S)-phenylglycinol salts. Halolacto-
nization to 333 was accomplished with NBS instead of the more
expensive iodine. Deprotection of the amine group was performed
with cheap HCl/EtOAc instead of TFA. To avoid epimerization, an
equimolar amount of base was used for the rearrangement of (3S)-
334b to (3S)-335. The original oxidation procedure required
expensive pyridine·SO3 and produced stoichiometric amounts oftoxic Me2S gas, while the improvedmethod used TEMPO and cheap
bleach. Fluorination time was successfully reduced from 4 days to
5e10 h with the use of SiO2 catalyzing the process. After ﬂuorina-
tion, to avoid chromatographic puriﬁcation, unreacted (R)-336was
removedwith selective hydrolysis, then treatment of the remaining
material with NaOH and bleach hydrolyzed the ester groups and
oxidatively decomposed the ﬂuorovinyl by-product. Upon acidiﬁ-
cation of this reaction mixture pure (R)-338 precipitated (Scheme
65). To sum up, with toxic and hazardous reagents avoided as
much as possible, the overall yield increased to 4.5% and the
calculated sum of all materials needed to produce 1 kg (R)-338
decreased to 2 t from 7 t [114].
Demange et al. synthesized 3-ﬂuoro-L-proline derivatives from
(2S,3S)-3-hydroxyproline 339. Protection of the carboxylic acid and
the amine gave esters 340a-b, which were reacted with DAST to
produce protected (2S,3R)-3-ﬂuoroproline derivatives 341a-b. Hy-
drolysis of 341a resulted in elimination of HF, but hydrogenolysis of
341b worked satisfactorily. Compound 342b was obtained from
340b its C3-epimer with the Mitsunobu reaction and protecting
group exchanges. This compound was transformed into (2S,3S)-3-
ﬂuoroproline derivative 343b with ﬂuorination and
Scheme 71. Synthesis of constrained ﬂuorinated proline analogue (±)-376. [121].
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During their work towards 3-ﬂuoroazetidinecarboxylic acids,
Liu et al. transformed 345 the diacetonide of 3-ﬂuoro-D-glucose to
hydroxymethylated 3-ﬂuoroazetidinecarboxylic acid derivative
348. Further ﬂuorination of this compound with XtalFluor-E
resulted in ring expansion through an aziridinium ion. The ob-
tained (3R,4R)-diﬂuoro-L-proline derivative 350 was subsequently
deprotected to the free (3R,4R)-diﬂuoro-L-proline (Scheme 67)
[116].
Doebelin et al. aimed at the development of a new, scalable and
fast synthetic route to enantiomerically pure 3,3-diﬂuoroproline.
The study startedwith ﬂuorination of the commercially available 3-
oxoproline derivative (±)-352a. Under normal conditions, the
conversion was not satisfying, but a clean and effective reaction
could be achieved with neat DAST. Subsequent protecting group
exchange provided racemic 3,3-diﬂuoroproline derivative (±)-354.
To improve and scale up this process, 3-oxoproline derivative
(±)-352bwas synthesized and ﬂuorinated. After removal of the tBu
group, resolution of the obtained (±)-354 with tyrosine hydrazide
enantiomers efﬁciently produced enantiomerically pure D- and L-
354, which were deprotected with hydrogenolysis almost quanti-
tatively (Scheme 68) [117].
Chen et al. carried out monoﬂuorination of bicyclic proline
analogue 363 by reduction of ketone 360 with a combined yield of
97% for 361 and 366 its epimer. Deoxyﬂuorination of major product
361 and deprotection gave the required product (Scheme 69).
Compound 363 was used as a building block for tripeptidyl a-
ketoamide rhinovirus 3C protease inhibitors [118]. Yip et al. applied
the same strategy to synthesize 363 and related diﬂuorinated
bicyclic proline analogue 365, which were used to construct HCV
protease inhibitors (Scheme 69) [119]. A more detailed synthesis of
(±)-362 (Cbz-protected 363) was reported by Johnson et al.
including its complete deprotection. Interestingly, upon ﬂuori-
nating a mixture of (±)-361 and (±)-366, the major alcohol wascleanly ﬂuorinated, while the minor alcohol yielded only an elim-
ination product. Access to pure (±)-362 was possible only after
dihydroxylation of the elimination product (Scheme 70) [120].
Jenkins et al. synthesized ﬂuorinated constrained proline
analogue (±)-376 from azetidine (±)-369 obtained from pyridine. In
the ﬁrst step construction of the rigid skeleton was carried out,
which was followed by multiple protection and deprotection steps.
During these processes the removal of Br and oxidation of CH2OH to
CO2H took place. Interestingly, the ﬁnal deoxyﬂuorination step
resulted in retention with a possible neighboring group participa-
tion (Scheme 71) [121].
In order to have access to proline derivatives with a CH2F group
at C-5, Mykhailiuk and co-workers attempted ﬂuorination of
racemic 5-hydroxymethylprolines obtained in a multistep synthe-
sis. As a result of a ring expansion side reaction, both the desired 5-
ﬂuoromethyl-prolines and 5-ﬂuoropipecolic acids were formed
(Scheme 72) [122].
The synthesis of 5,5-diﬂuoropipecolic acid derivatives was re-
ported by two research groups. Golubev et al. obtained 5-
ketopipecolic acid derivative 389 analogously to the preparation
of 4-ketoproline derivative shown on Scheme 58 including a suc-
cessful deoxyﬂuorination (Scheme 73) [123]. Singh and co-workers,
in turn, prepared 5-hydroxypipecolic acid derivative (±)-393 from
readily available 5,6-didehydropipecolate (±)-392 followed by
Swern oxidation and deoxyﬂuorination (Scheme 74) [124].
Ishikawa and co-workers synthesized ﬂuorinated octahy-
dropyrrolo[1,2-a]pyrazine derivative 401 from cis-4-hydroxy-D-
proline, which served as a building block for inhibitor of apoptosis
protein (IAP) antagonists. The heterocyclic skeleton was con-
structed by reduction of the amide moiety in 397 and reaction of
the resulting 1,2-diamine intermediate with 2,3-
dibromopropanoate. Subsequent oxidation and deoxyﬂuorination
gave compound 401 (Scheme 75) [74].
Monn et al. synthesized multiple 4-substituted 2-aminobicyclo
Scheme 72. Synthesis of racemic 5-ﬂuoromethylprolines and 5-ﬂuoropipecolic acids [122].
Scheme 73. Synthesis of 5,5-diﬂuoropipecolic acid and its derivatives [123].
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Scheme 74. Synthesis of N-protected 5,5-diﬂuoropipecolic acid methyl ester [124].
Scheme 75. Synthesis of ﬂuorinated octahydropyrrolo[1,2-a]pyrazinecarboxylic acid derivative 401 [74].
Scheme 76. Synthesis of 4-ﬂuoro-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid 407 [125].
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as potential metabotropic glutamate 2/3 receptor agonists. The
synthesis started with cyclopropanation of enone 402, followed by
diastereoselective reduction, deoxyﬂuorination and deprotection
(Scheme 76) [125].
Because of the tumor speciﬁcity of 1-
aminocyclobutanecarboxylic acid, its 18F-containing derivatives
gained interest as possible PET tracers. As a result, multiple
research groups focused on the synthesis of these compounds and
their non-radioactive counterparts used as cold reference.
[126e128] Shoup and Goodman reported the synthesis of (1r*,3r*)-
3-ﬂuoro-1-aminocyclobutanecarboxylic acid (±)-416a fromepichlorohydrin, benzyl bromide and diethyl malonate (Scheme
77) [126]. Yu et al. synthesized its (1r*,3s*)-stereoisomer in a
similar manner. The main difference was that compounds
(±)-418a,b were not separated, but oxidized to ketone 419 after
protection and debenzylation. Ketone 419 underwent diaster-
eoselective reduction yielding (1r*,3r*)-alcohol (±)-418b, which
was ﬂuorinated and deprotected (Scheme 78) [127]. Goodman and
co-workers reported the synthesis of (1R*,2S*)-1-amino-2-
ﬂuorocyclobutanecarboxylic acid by deoxyﬂuorination of the
appropriately protected hydroxy amino acid precursor (Scheme 79)
[128].
Scheme 77. Synthesis of (1r*,3r*)-3-ﬂuoro-1-aminocyclobutanecarboxylic acid [126].
Scheme 78. Synthesis of (1r*,3s*)-3-ﬂuoro-1-aminocyclobutanecarboxylic acid [127].
Scheme 79. Synthesis of (1R*,2S*)-1-amino-2-ﬂuorocyclobutanecarboxylic acid [128].
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Selective synthetic methods towards various ﬂuorinated cyclic
b-amino acid derivatives have been comprehensively summarized
in a recent review by Kiss et al. [129] incorporating the most rele-
vant routes to this class of derivatives. In most cases, late-stage
deoxyﬂuorination was performed on b-amino acid derivatives hy-
droxylated regio- and stereoselectively (synthesized by iodo-
lactionization, iodooxazinone formation or oxirane ring opening) orketo-b-amino acid derivatives (obtained by oxidation of the pre-
vious compounds). Late-stage ﬂuorination by ring opening of
aziridinated b-amino acid derivatives with XtalFluor-E was also
included [129]. Accordingly, the current review focuses only on
pathways not covered by the above-mentioned account including
other recently published results.
In order to obtain conformationally constrained b-amino acids,
Vera-Ayoso et al. synthesized ﬂuorinated b-amino acid derivative
429 from methyl b-D-glucopyranoside 424. Oxidation with NaIO4,
Scheme 80. Synthesis of conformationally constrained b-amino acid derivative 429 on a carbohydrate basis [130].
Scheme 81. Synthesis of ﬂuorinated b-amino acid derivatives [133] through isoxazole-fused b-amino acid derivatives [131e133].
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Scheme 82. Synthesis of CHF2-containing b-amino acids by ﬂuorination of dialdehydes [134].
Scheme 83. Synthesis of ﬂuorinated b-amino acid derivatives by oxirane ring opening with Deoxoﬂuor [24].
Scheme 84. Synthesis of ﬂuoromethyl-containing b-amino acid derivatives [135]. Synthesis of (±)-445 and (±)-454 is shown on Scheme 82.
Scheme 85. Synthesis of ﬂuorinated b-amino acid derivatives by ﬂuorination of dihydroxylated b-amino acid derivatives [25].
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Scheme 86. Synthesis of diﬂuoromethyl- and ﬂuorovinyl-containing b-amino acid derivatives from b-amino acids derived a,b-unsaturated aldehydes [136].
Scheme 87. Synthesis of ﬂuorinated cyclic GABA aminotransferase inhibitor analogues [137]. Stereochemistry of 511 and (þ)-512 was corrected according to [138]. PMB¼ 4-
methoxybenzyl.
Scheme 88. Synthesis of N-Boc-protected ﬂuorinated cyclic g-amino acids [138]. PMB¼ 4-methoxybenzyl.
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OH groups as cyclic acetal resulted in compound 427. After reduc-
tion of the cyano group, the free OH group was reacted with DAST
giving product 429 with the participation of the neighboring
methoxy group (Scheme 80) [130].
Nonn et al. reported the synthesis of multifunctional b-amino
acid derivatives (±)-435a-c and (±)-437a,b by nitrile oxide [3 þ 2]
dipolar cycloaddition to protected 2-aminocyclopent-3-
enecarboxylates and subsequent reductive opening of their het-
erocyclic ring [131e133]. These hydroxyl-containing derivatives
underwent deoxyﬂuorination yielding ﬂuorine-containing de-
rivatives and elimination products (Scheme 81) [133].
Kiss et al. synthesized diﬂuoromethyl-containing b-amino acids
from dihydroxylated compounds (±)-444, (±)-449 and (±)-453
prepared from norbornene b-amino acids. After oxidative ringopening with NaIO4, the dialdehyde products were reacted with
Deoxoﬂuor. (±)-445 gave two products formed in a temperature-
dependent manner. At 0 C, (±)-447 was formed exclusively with
the 5-formyl group transformed into CHF2, while the 3-formyl
group participated in cyclization with the amide group. At 20 C,
product (±)-446 was also formed through the transformation of
both formyl groups into CHF2 groups. Interestingly, reaction of
(±)-450 with Deoxoﬂuor also gave (±)-447 suggesting that basic
ﬂuoride ions cause isomerization at C-3 and C-5 before ﬂuorination
can occur. The behavior of dialdehyde (±)-454was similar to that of
(±)-445 (Scheme 82) [134].
Remete et al. developed a newmethod for oxirane ring opening
with the successful use of Deoxoﬂuor in the transformation of ep-
oxides derived from unsaturated b-amino esters. Fluorohydrines
produced by initial epoxide ring opening were often transformed
Scheme 89. Synthesis of conformationally restrained GABA analogues [139].
Scheme 90. Synthesis of oxetane d-amino acids from carbohydrates [140].
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Scheme 91. Synthesis of ﬂuorinated cyclic amino acids from aziridines [141].
Scheme 92. Synthesis of 2,3-diﬂuorosialic acid analogue [142].
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with low yields (Scheme 83) [24].
Kiss et al. synthesized ﬂuoromethyl-containing b-amino-
cyclopentanecarboxylic acid derivatives as well. Dialdehydes
(±)-445, (±)-454 and (±)-475 were reduced with NaBH4 to the
corresponding diols (±)-469, (±)-471 and (±)-476. Fluorination of
(±)-471 resulted in the formation of two CH2F groups, while in the
reaction of (±)-469 and (±)-476 with Deoxoﬂuor, the 3-
hydroxymethyl and NHBz groups were involved in the formation
of a heterocycle (Scheme 84). Reduction of (±)-450 and the C-1
epimer of (±)-445 were also performed, but the incorporation ofﬂuorine into the products failed [135].
Remete et al. also prepared ﬂuorinated b-amino acid derivatives
through the reaction of dihydroxylated b-amino acid derivatives
with Deoxoﬂuor. These starting materials are readily available by
dihydroxylation of N-protected b-aminocycloalkenecarboxylates.
Participation of the neighboring protected amino group often
resulted in cyclization with or without ﬂuorination. Examples
where ﬂuorine incorporation was successful are shown on Scheme
85. Interestingly, ﬂuorination of some diols yielded cyclic g-amino
acid derivatives by rearrangement through an aziridinium ion in-
termediate (see Scheme 94). It is also worth to note that
Scheme 93. Synthesis of azide-bearing 2,3-diﬂuorosialic acid analogues [143].
Scheme 94. Synthesis of ﬂuorinated g-amino acid derivatives from b-amino acid [136].
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otherwise, only cyclic sulﬁtes were formed [25].
Remete et al. also transformed a,b-unsaturated aldehydes to
diﬂuoromethyl-containing b-amino acid derivatives. These com-
pounds were obtained from dihydroxylated b-amino acid de-
rivatives by oxidative ring opening and subsequent intramolecular
aldol condensation. Unfortunately, diol (±)-483 and its C-1 epimer
gave unseparable mixtures of two aldehydes. In the case of (±)-487
and (±)-488, however, the aldol reaction was regioselective, pre-
sumably, because the other possible aldol product cannot be
dehydrated through an E1cb mechanism. Fluorination of the ob-
tained aldehydes (±)-490a,b resulted in two products induced by
the allylic structure of intermediate (±)-491a,b. Diﬂuorinated
compounds (±)-492a,bwere formed by direct displacement of the
leaving group with ﬂuoride affording ﬂuorovinyl compounds(±)-493a,b formed by SN20 attack of the amide oxygen (Scheme 86)
[136].
2.6. Synthesis of other cyclic ﬂuorinated amino acid derivatives
Silverman and co-workers reported the synthesis of multiple-
ﬂuorinated 3-aminocyclopentane carboxylic acids as analogues of
GABA aminotransferase inhibitors. In order to synthesize (þ)-500,
protected ()-enantiomer of Vince lactam was reacted with a Brþ
source in AcOH bringing about rearrangement to 496. After acetate
hydrolysis, ﬂuorination, reductive debromination and debenzyla-
tion, lactame hydrolysis provided free acid (þ)-500. In order to
obtain (þ)-502, lactam 501 was hydrolyzed. This g-lactam was
synthesized analogously to 498 but with 4-methoxybenzyl as N-
protecting group, which was ﬁnally removed with cerium(IV)
Table 1
Synthesis of (2S,4S)-4-ﬂuoroproline derivatives 299a-e.
Compound PG R Fluorination Yield Reference
298a Boc Me DAST, CH2Cl2, -78 C to RT 81% [99]
DAST, CH2Cl2, 0 C to RT, 14 h 85% [21]
DAST, CH2Cl2, -78 C to RT, 24 h 78% [100]
DAST, CH2Cl2, -78 C to RT, overnight 74% [101]
298b Fmoc Bn MOST, CH2Cl2, -80 C to RT, 48 h 80% [102]
298c Boc Bn MOST, CH2Cl2, -78 C to RT, overnight 48% [103]
298d Boc PhCOCH2 MOST, CH2Cl2, -78 C to RT, 48 h 94% [104]
298e Cbz Me XtalFluor-E, DBU, CH2Cl2, -78 C to RT 82% [105]
Table 2
Synthesis of (2S,4R)-4-ﬂuoroproline derivatives 301a-d and 301j. After the compound numbers, PG and R are given in parentheses where needed.
Product PG0 R0 Conditions and yields Reference
301a Boc Me 298k (CPh3, Me)/ 300k (CPh3, Me): 58%
1. PPh3, DEAD, PhCO2H, PhMe
2. KOH/MeOH
300k (CPh3, Me)/ 300a (Boc, Me): 86%
1. HCO2H, ClCH2CH2Cl
2. Boc2O, Et3N
300a/ 301a: 63%
DAST, CH2Cl2, -78 C to RT
[99]
298f (Boc, H)/ 300f (Boc, H):
1. MsCl, CH2Cl2, 0 C, overnight, 78%
2. iPr2NEt, dioxane, 95 C, 2 h, 78%
3. LiOH, MeOH/THF/H2O 2:2:3, RT, overnight, 95%
300f (Boc, H)/300a (Boc, Me): 74%
MeI, K2CO3, DMF, 0 C, overnight
300a/ 301a: 34%
DAST, CH2Cl2, -78 C to RT, overnight
[101]
301b Fmoc Bn 300b/ 301b:
MOST, CH2Cl2, -80 C to RT, 48 h, 83%
[102]
301c Boc Bn 298c/ 300c:
1. PPh3, DIAD, p-nitrobenzoic acid, THF
0 C, 3 h, 93%
2. KHCO3, dioxane/MeOH/H2O, RT, 14 h, 79%
300c/ 301c: 55%
DAST, CH2Cl2, -78 C to RT, 20 h
[103]
301d Boc PhCOCH2 298a (Boc, Me)/300f (Boc, H): 78%
PPh3, DEAD, HCO2H, THF, PhMe, RT, overnight; then 1M NaOH, RT, 1 h
300f (Boc, H)/300d (Boc, PhCOCH2): 87%
1. Cs2CO3, MeOH/H2O, 0 C
2. PhCOCH2Br, DMF, 0 C, 30min
300d/ 301d: 79%
MOST, THF, 78 C to RT, 48 h
[104]
301j Cbz Bn 298j/ 300j:
1. PPh3, DIAD, p-nitrobenzoic acid, THF
78 C, 70%
2. KHCO3, dioxane/MeOH/H2O, 60%
300j/ 301j: 50%
DAST or MOST, CH2Cl2, -78 C
[106]
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Table 3
Synthesis of (2S,4S)-4-ﬂuoropyrrolidine-2-carbonyl ﬂuorides 308a-d and (2S,4R)-4-ﬂuoropyrrolidine-2-carbonyl ﬂuoride 309. Isolated yields are in parentheses, other yields
are based on 19F NMR using PhF as a standard [108].
Substrate Product PG Fluorination Yield
298f 308a Boc 2.5 eq. FluoLead, CH2Cl2, 0 C to RT, 1 h; then RT, 45 h 27%
2.5 eq. FluoLead, 0.5 eq. pyridine, CH2Cl2
0 C to RT, 1 h; then RT, 45 h
90%
3 eq. FluoLead, 0.25 eq. Et3N, CH2Cl2, 0 C to RT, 1 h; then RT, 45 h 77%
298g 308b Fmoc 2.5 eq. FluoLead, CH2Cl2, 0 C to RT, 1 h; then RT, 60 h 90% (78%)
2.5 eq. FluoLead, 0.1 eq. pyridine·9HF
CH2Cl2, 0 C to RT, 1 h; then RT, 22 h
100% (88%)
2.5 eq. FluoLead, 0.4 eq. pyridine·9HF
CH2Cl2, 0 C to RT, 1 h; then RT, 5 h
92% (84%)
298m 308c Cbz 2.5 eq. FluoLead, CH2Cl2, 0 C to RT, 1 h; then RT, 60 h 90% (75%)
298o 308d ClCH2CO 2.5 eq. FluoLead, CH2Cl2, 0 C to RT, 1 h; then RT, 72 h 90% (76%)
300k 309 Fmoc 2.5 eq. FluoLead, CH2Cl2, 0 C to RT, 1 h; then RT, 60 h 36%
A.M. Remete et al. / Tetrahedron 74 (2018) 6367e64186416ammonium nitrate. Racemic 503, accessed from (±)-494 (protec-
tion, bromoacetoxylation, reductive debromination and acetate
hydrolysis), underwent oxidation, ﬂuorination, N-deprotection and
hydrolysis to provide diﬂuorinated amino acid (±)-507. In the case
of (þ)-512, PMB-protected ()-Vince lactam underwent epoxida-
tion and then was reacted with HBr. The resulting bromohydrin
isomers were inseparable, but their trimethylsilyl ethers could be
separated successfully. After desilylation, pure 510was subjected to
ﬂuorination, N-deprotection and lactame hydrolysis, resulting in
(þ)-512 (Scheme 87) [137].
Granja and co-workers used a quite similar strategy to synthe-
size racemic ﬂuorinated g-amino acid derivatives applied as fol-
damer building blocks (Scheme 88). They also corrected the results
of [137] reporting that ﬂuorination of [2.2.1] bicyclic lactams at the
apical carbon takes place with retention of conﬁguration [138].
Wang et al. synthesized two ﬂuorinated, conformationally
restrained GABA analogues as potential GABA aminotransferase
inhibitors. all-cis Hydroxylated g-aminocyclohexanecarboxylic acid
derivatives (±)-526 and (±)-532 were obtained by catalytic hy-
drogenation of the aromatic precursors followed by protection
steps, and then (±)-532 was oxidized into (±)-533. Fluorination of
(±)-526 and (±)-533 and subsequent deprotection resulted in
target molecules (±)-529 and (±)-535 (Scheme 89) [139].
Oxetane d-amino acids, useful chiral scaffolds, were prepared by
Lucas et al. from carbohydrates in 10e14 steps. The ester group was
created by anomeric oxidation and the oxetane moiety was con-
structed by ring contraction. Nitrogen was introduced into 3-
hydroxy-4-(hydroxymethyl)oxetane-2-carboxylates by sulfonyla-
tion of their primary OH followed by displacement with azide ion.
The resulting azidoalcohols (538 and 544) were ﬂuorinated, the
azide group was reduced and the methyl ester moiety was hydro-
lyzed to obtain ﬁnal products 540 and 546 (Scheme 90) [140].
Nonn et al. used their aziridine ring opening method with
XtalFluor-E to synthesize ﬂuorinated cyclic g- and d-amino acids
too (Scheme 91) [141].
Dirr et al. synthesized multiple 2,3-diﬂuorosialic acid analogues
to study the mechanism of human parainﬂuenza virus type 3
haemagglutin-neuraminidase. The ﬁrst ﬂuorine atom was intro-
duced through the reaction of unsaturated 553 with electrophilic
ﬂuorinating agent Selectﬂuor in the presence of water. The OH
group formed during this process was then exchanged to ﬂuorinewith DAST. Finally, the O-acetyl groups and the methyl ester was
hydrolyzed to obtain analogues 559e561 (Scheme 92) [142].
Yang et al. used a similar strategy to obtain azide-containing 2,3-
diﬂuorosialic acid analogues. The diastereomeric mixtures of
563þ 564 and 565 þ 566were inseparable. Although separation of
567 and 568 was successful, only their combined yield was re-
ported (Scheme 93). These analogues were attached through click
reaction to appropriate polyynes to provide di-, tri-, tetra- and
octavalent zanamivir analogues [143].
While studying the ﬂuorination of dihydroxylated cyclic b-
amino acids, Remete et al. observed that in some cases ﬂuorinated
g-amino acid derivatives were formed by aziridine formation and
subsequent aziridine ring opening (Scheme 94) [136].
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